SECONDARY MYELODYSPLASTIC SYNDROME
Clinical trials for SECONDARY MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new SECONDARY MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for SECONDARY MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to control aggressive cancer triggered by chemotherapy
Disease control OngoingThis study is testing whether combining two drugs, venetoclax and azacitidine, works better than standard care for patients with therapy-related myelodysplastic syndrome (t-MDS). t-MDS is a serious bone marrow disorder that can develop after a person receives chemotherapy or radi…
Matched conditions: SECONDARY MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated Apr 04, 2026 04:50 UTC
-
Scientists test Immune-Boosting combo against tough blood cancers
Disease control OngoingThis early-stage study is testing the safety and best dose of a two-drug combination for patients with advanced myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The trial combines a chemotherapy drug (decitabine…
Matched conditions: SECONDARY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New transplant strategy aims to tame tough blood cancers
Disease control OngoingThis study is testing a two-drug chemotherapy regimen followed by a donor stem cell transplant for adults with certain blood cancers that are in remission or at high risk. The goal is to see if this approach can better control the disease and prevent it from coming back after the…
Matched conditions: SECONDARY MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC